Cargando…

Targeting the Interplay between Cancer Metabolic Reprogramming and Cell Death Pathways as a Viable Therapeutic Path

In cancer cells, metabolic adaptations are often observed in terms of nutrient absorption, biosynthesis of macromolecules, and production of energy necessary to meet the needs of the tumor cell such as uncontrolled proliferation, dissemination, and acquisition of resistance to death processes induce...

Descripción completa

Detalles Bibliográficos
Autores principales: Iessi, Elisabetta, Vona, Rosa, Cittadini, Camilla, Matarrese, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698563/
https://www.ncbi.nlm.nih.gov/pubmed/34944758
http://dx.doi.org/10.3390/biomedicines9121942
_version_ 1784620307079757824
author Iessi, Elisabetta
Vona, Rosa
Cittadini, Camilla
Matarrese, Paola
author_facet Iessi, Elisabetta
Vona, Rosa
Cittadini, Camilla
Matarrese, Paola
author_sort Iessi, Elisabetta
collection PubMed
description In cancer cells, metabolic adaptations are often observed in terms of nutrient absorption, biosynthesis of macromolecules, and production of energy necessary to meet the needs of the tumor cell such as uncontrolled proliferation, dissemination, and acquisition of resistance to death processes induced by both unfavorable environmental conditions and therapeutic drugs. Many oncogenes and tumor suppressor genes have a significant effect on cellular metabolism, as there is a close relationship between the pathways activated by these genes and the various metabolic options. The metabolic adaptations observed in cancer cells not only promote their proliferation and invasion, but also their survival by inducing intrinsic and acquired resistance to various anticancer agents and to various forms of cell death, such as apoptosis, necroptosis, autophagy, and ferroptosis. In this review we analyze the main metabolic differences between cancer and non-cancer cells and how these can affect the various cell death pathways, effectively determining the susceptibility of cancer cells to therapy-induced death. Targeting the metabolic peculiarities of cancer could represent in the near future an innovative therapeutic strategy for the treatment of those tumors whose metabolic characteristics are known.
format Online
Article
Text
id pubmed-8698563
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86985632021-12-24 Targeting the Interplay between Cancer Metabolic Reprogramming and Cell Death Pathways as a Viable Therapeutic Path Iessi, Elisabetta Vona, Rosa Cittadini, Camilla Matarrese, Paola Biomedicines Review In cancer cells, metabolic adaptations are often observed in terms of nutrient absorption, biosynthesis of macromolecules, and production of energy necessary to meet the needs of the tumor cell such as uncontrolled proliferation, dissemination, and acquisition of resistance to death processes induced by both unfavorable environmental conditions and therapeutic drugs. Many oncogenes and tumor suppressor genes have a significant effect on cellular metabolism, as there is a close relationship between the pathways activated by these genes and the various metabolic options. The metabolic adaptations observed in cancer cells not only promote their proliferation and invasion, but also their survival by inducing intrinsic and acquired resistance to various anticancer agents and to various forms of cell death, such as apoptosis, necroptosis, autophagy, and ferroptosis. In this review we analyze the main metabolic differences between cancer and non-cancer cells and how these can affect the various cell death pathways, effectively determining the susceptibility of cancer cells to therapy-induced death. Targeting the metabolic peculiarities of cancer could represent in the near future an innovative therapeutic strategy for the treatment of those tumors whose metabolic characteristics are known. MDPI 2021-12-18 /pmc/articles/PMC8698563/ /pubmed/34944758 http://dx.doi.org/10.3390/biomedicines9121942 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Iessi, Elisabetta
Vona, Rosa
Cittadini, Camilla
Matarrese, Paola
Targeting the Interplay between Cancer Metabolic Reprogramming and Cell Death Pathways as a Viable Therapeutic Path
title Targeting the Interplay between Cancer Metabolic Reprogramming and Cell Death Pathways as a Viable Therapeutic Path
title_full Targeting the Interplay between Cancer Metabolic Reprogramming and Cell Death Pathways as a Viable Therapeutic Path
title_fullStr Targeting the Interplay between Cancer Metabolic Reprogramming and Cell Death Pathways as a Viable Therapeutic Path
title_full_unstemmed Targeting the Interplay between Cancer Metabolic Reprogramming and Cell Death Pathways as a Viable Therapeutic Path
title_short Targeting the Interplay between Cancer Metabolic Reprogramming and Cell Death Pathways as a Viable Therapeutic Path
title_sort targeting the interplay between cancer metabolic reprogramming and cell death pathways as a viable therapeutic path
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698563/
https://www.ncbi.nlm.nih.gov/pubmed/34944758
http://dx.doi.org/10.3390/biomedicines9121942
work_keys_str_mv AT iessielisabetta targetingtheinterplaybetweencancermetabolicreprogrammingandcelldeathpathwaysasaviabletherapeuticpath
AT vonarosa targetingtheinterplaybetweencancermetabolicreprogrammingandcelldeathpathwaysasaviabletherapeuticpath
AT cittadinicamilla targetingtheinterplaybetweencancermetabolicreprogrammingandcelldeathpathwaysasaviabletherapeuticpath
AT matarresepaola targetingtheinterplaybetweencancermetabolicreprogrammingandcelldeathpathwaysasaviabletherapeuticpath